Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: Migaldendranib in Healthy Volunteers Trial completed
- Minor: Eloralintide (LY3841136) · Renal Impairment and in Participants With Normal Renal Function Trial completed
- Minor: Real-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief Trial completed
- Minor: DOT Spectacles in Chinese Children Extension Enrollment closed, study ongoing
- Minor: Collection of Blood Samples for New Diagnostic Devices 2 Trial completed
- Minor: Korean Post-marketing Surveillance for Xeljanz XR Trial completed
- Minor: Activia Kefir Consumption in Real-world Setting Enrollment closed, study ongoing
- Minor: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Enrollment closed, study ongoing
- Minor: Specific Gait Patterns · Multiple Sclerosis Trial completed
- Minor: Etrasimod · Moderate to Severe Ulcerative Colitis Enrollment closed, study ongoing
- Minor: Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease Trial completed
- Minor: Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea Enrollment closed, study ongoing
- Minor: Iovera®° System · Upper Extremity Spasticity Trial completed
- Minor: SPN-812 (Viloxazine Extended-release Capsule) Primary and study completion pushed from Sep 2026 to Dec 2026
- Minor: Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy Enrollment closed, study ongoing
- Minor: AZA+Lus VS AZA Monotherapy in HR-MDS Completed without a posted recruiting period
- Minor: Recurrent Breast Cancer and Repeated Radiation Therapy Enrollment closed, study ongoing
- Minor: Surgical Approach in Hemiarthroplasty. A Randomized Clinical Trial Comparing Posterior and Anterior Approach Trial completed
- Minor: 18F-mFBG Imaging for Myocardial Sympathetic Innervation Primary completion pushed from Oct 30, 2026 to Mar 30, 2027
- Minor: 18F-mFBG Cardiac Uptake With Lewy Body Dementia Primary completion pushed from Oct 30, 2026 to Mar 30, 2027
- Minor: Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax Enrollment closed, study ongoing
- Minor: Biodistribution of [177Lu]Lu-ABY-271 · HER2-positive Metastatic Breast Cancer Primary completion pushed from Jan 1, 2027 to Jun 1, 2027
- Minor: LY4057996 in Healthy Participants and · Type 1 and Type 2 Diabetes Primary and study completion pushed from Mar 2027 to Jul 2027
- Minor: Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity Enrollment closed, study ongoing
- Minor: Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial) Trial completed
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates